More than 90% of emerging market funds are adding back their positions in mainland Chinese shares, which were underweight, while also diali...

Syngene is a fully integrated CRAMS company and Biocon has around 70% stake in it. Syngene also has a wholly-owned subsidiary in the US.

At the close, the Shanghai Composite index was up 0.67% at 3,452.63. The blue-chip CSI300 index fell 0.55%, recovering after it hit a 19-mo...

Test details for the dual-antibody treatment, which last week became the first approved COVID-19 antibody cocktail in China, would not be a...

China Evergrande Group plunged nearly 12% to its lowest in more than six years, after it warned of a risk of cross-default as real estate s...

As equity valuations turn expensive amid the recordbreaking rally, financial planners are telling investors to diversify their stock portfo...

The pharmaceutical industry increasingly relies for its profits on costly biologic drugs, made from living organisms that are tougher and m...

“A combination of improved macros and a weaker dollar generally bodes well for emerging markets flows.”

The change announced by the Hang Seng Indexes Company on Friday was made possible after the 50-year-old benchmark's publisher changed the r...

Syngene, an arm of Biocon, is expanding its capital investment as it waits to complete a 40-acre, $100-million research facility in Mangalo...

Biocon plans to raise Rs 550 crore by diluting 11% stake in Syngene through the Initial Public Offer. The proceeds will mostly go into fund...

"The biggest problem is that investors do not want us to spend on R&D and R&D is a very integral part of our business."